Michael R. Migden

Peer-Reviewed Articles

1. Joshi TP, Sorrels C, Migden MR. Risk of Associated Visceral Malignancies in Patients With Extra-anogenital Extramammary Paget Disease. Dermatol Surg, 2025. e-Pub 2025. PMID: 41343558.
2. Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, Xie T, Balood M, Adewale A, Naara S, Sathishkumar HN, Islam S, McCarthy W, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Roversi K, Nikpoor AR, Ahmadi M, Ahmadi A, Harwood C, Leigh I, Gong D, Tallon de Lara P, Tao DL, Davidson TM, Ajami NJ, Futreal A, Rai K, Kochat V, Castillo M, Gunaratne P, Goepfert RP, Hernandez SD, Khushalani NI, Wang J, Watowich SS, Calin GA, Migden MR, Yuan M, Liu N, Ye Y, Hwang WL, Vermeer PD, D'Silva NJ, Bunimovich YL, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo JA, Myers JN, Talbot S, Gross ND, Amit M. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature 646(8084):462-473, 2025. e-Pub 2025. PMID: 40836096.
3. Joshi TP, Engineer N, Husseinali M, Migden MR. No Association Between Ambient Ultraviolet Exposure and Cutaneous Leiomyosarcoma Incidence in the United States: An Ecological Study Using Surveillance, Epidemiology, and End Results-NASA. Dermatol Surg, 2025. e-Pub 2025. PMID: 40720846.
4. Migden MR, Kheterpal M, Moody B, Patel K, Lionnet L, Sivam S, Conti J, Squittieri N, Farberg AS. Efficacy following discontinuation of sonidegib 200 mg daily treatment in patients with locally advanced basal cell carcinoma: Post hoc analysis of the 42-month BOLT study. J Am Acad Dermatol 93(2):468-471, 2025. e-Pub 2025. PMID: 40246082.
5. Joshi TP, Patel K, Migden MR. Incidence, Tumor Characteristics, and Survival of Patients With Cutaneous Apocrine Carcinoma: A Retrospective Study of 323 Patients in the Surveillance, Epidemiology, and End Results Program. Dermatol Surg 51(8):815-817, 2025. e-Pub 2025. PMID: 40152356.
6. Gaudy-Marqueste, C, Grob, JJ, Garbe, C, Ascierto, PA, Arron, ST, Basset-Seguin, N, Bohne, AS, Lenoir, C, Dummer, R, Fargnoli, MC, Guminski, A, Hauschild, A, Kaufmann, R, Lallas, A, del Marmol, V, Migden, MR, Penicaud, M, Rembielak, A, Stratigos, A, Tagliaferri, L, Zalaudek, I, Arance, A, Badinand, D, Bossi, P, Challapalli, A, Clementi, M, Di Stefani, A, Ferrándiz-Pulido, C, Giuffrida, R, Gravina, GL, Ha, PK, Heinzerling, L, Mallet, S, Paradisi, A, Mohr, P, Piccerillo, A, Rutkowski, D, Saïag, P, Sollena, P, Trakatelli, M, Wojcieszek, PA, Yom, SS, Zelin, E, Peris, K, Malvehy, J. Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts. Journal of the European Academy of Dermatology and Venereology 39(3):612-621, 2025. e-Pub 2025. PMID: 38961704.
7. Gali, LL, Lazaroff, JM, Migden, MR. How We Do It. Dermatologic Surgery 51(3):333-335, 2025. e-Pub 2025. PMID: 39584696.
8. Hughes, BG, Guminski, A, Bowyer, S, Migden, MR, Schmults, CD, Khushalani, N, Chang, AS, Grob, JJ, Lewis, K, Ansstas, G, Day, F, Ladwa, R, Stein, B, Muñoz-Couselo, E, Meier, F, Hauschild, A, Schadendorf, D, Basset-Seguin, N, Modi, B, Dalac-Rat, S, Dunn, LA, Flatz, L, Mortier, L, Guégan, S, Heinzerling, L, Mehnert, JM, Trabelsi, S, Soria-Rivas, A, Stratigos, A, Ulrich, C, Wong, DJ, Beylot-Barry, M, Bossi, P, Bugés Sánchez, C, Chandra, S, Robert, C, Russell, JS, Silk, AW, Booth, J, Yoo, SY, Seebach, F, Lowy, I, Fury, MG, Rischin, D. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1). Journal of the American Academy of Dermatology 92(1):68-77, 2025. e-Pub 2025. PMID: 39245360.
9. Migden, MR, Farberg, AS, Spencer, J, Kiecker, F, Guminski, A, Gebauer, K, Loquai, C, Robert, C, Dummer, R, Schadendorf, D, Hauschild, A, Grob, JJ, Squittieri, N, Arntz, R, Martelli, S, Dierlamm, J, Gutzmer, R. Sonidegib reduced tumor burden in patients with advanced basal cell carcinoma in the BOLT trial. EJC Skin Cancer 2, 2024. e-Pub 2024.
10. Rischin D, Hughes BGM, Basset-Séguin N, Schadendorf D, Bowyer S, Trabelsi Messai S, Meier F, Eigentler TK, Casado Echarren V, Stein B, Beylot-Barry M, Dalac S, Dréno B, Migden MR, Hauschild A, Schmults CD, Lim AM, Yoo SY, Paccaly AJ, Papachristos A, Nguyen JH, Okoye E, Seebach F, Booth J, Lowy I, Fury MG, Guminski A. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. J Immunother Cancer 12(3), 2024. e-Pub 2024. PMID: 38471711.
11. Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Fernández Orland A, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Yoo SY, Okoye E, Bassukas I, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Inocencio TJ, Chen CI, LaFontaine PR, Seebach F, Lowy I, Fury MG. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. J Am Acad Dermatol 90(2):414-418, 2024. e-Pub 2024. PMID: 37839734.
12. Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, Chang ALS, Migden MR, Yoo SY, Mohan K, Coates E, Okoye E, Bowler T, Baurain JF, Bechter O, Hauschild A, Butler MO, Hernandez-Aya L, Licitra L, Neves RI, Ruiz ES, Seebach F, Lowy I, Goncalves P, Fury MG. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol 35(2):221-228, 2024. e-Pub 2024. PMID: 38072158.
13. Baruch EN, Nagarajan P, Gleber-Netto FO, Rao X, Xie T, Akhter S, Adewale A, Shajedul I, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunaratne P, Goepfert RP, Khushalani N, Wang J, Watowich S, Calin GA, Migden MR, Vermeer P, D'Silva N, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo J, Myers JN, Gross ND, Amit M. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Res Sq, 2023. e-Pub 2023. PMID: 37503252.
14. Chen HY, Zhao W, Na'ara S, Gleber-Netto FO, Xie T, Ali S, Thompson ZM, Buell J, Stafford H, Nagarajan P, Davies M, Wong MK, Migden MR, Sharma P, Myers JN, Gross ND, Amit M. Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precis Oncol 7:e2200490, 2023. e-Pub 2023. PMID: 37285560.
15. Lear JT, Robert C, Grob JJ, Dummer R, Guminski A, Squittieri N, Migden M. Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. Eur J Dermatol 33(3):280-286, 2023. e-Pub 2023. PMID: 37594336.
16. Wilmas KM, Patel J, Silapunt S, Doan HQ, Migden MR. The Use of a Dehydrated Complete Human Placental Membrane Allograft for Mohs Surgical Defects of the Nose. Dermatol Surg 49(4):343-347, 2023. e-Pub 2023. PMID: 36799879.
17. Migden M, Loquai C, Robert C, Baurain JF, Squittieri N, Arntz R, Dierlamm J, Dréno B. Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks. JAAD Int 10:31-33, 2023. e-Pub 2023. PMID: 36425794.
18. Baig IT, Nguyen QD, Jahan-Tigh RR, Migden MR. Digital Photography for the Dermatologist. Clin Dermatol 41(1):171-177, 2023. e-Pub 2023. PMID: 36252727.
19. Rabinowits G, Migden MR, Schlesinger TE, Ferris RL, Freeman M, Guild V, Koyfman S, Pavlick AC, Swanson N, Wolf GT, Dinehart SM. Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID Innov 1(4):100045, 2021. e-Pub 2021. PMID: 34909742.
20. Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer 127(23):4413-4420, 2021. e-Pub 2021. PMID: 34358340.
21. Wilmas KM, Nguyen QB, Patel J, Silapunt S, Migden MR. Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. Future Oncol 17(35):4971-4982, 2021. e-Pub 2021. PMID: 34608809.
22. Lewis K, Dummer R, Farberg AS, Guminski A, Squittieri N, Migden M. Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. Dermatol Ther (Heidelb) 11(6):2225-2234, 2021. e-Pub 2021. PMID: 34669179.
23. Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34413166.
24. Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 22(6):848-857, 2021. e-Pub 2021. PMID: 34000246.
25. Paccaly AJ, Migden MR, Papadopoulos KP, Yang F, Davis JD, Rippley RK, Lowy I, Fury MG, Stankevich E, Rischin D. Fixed dose of cemiplimab in patients with advanced malignancies based on population pharmacokinetic analysis. Adv Ther 38(5):2365-2378, 2021. e-Pub 2021. PMID: 33768419.
26. Amit M, Liu C, Gleber-Netto FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Baruch EN, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer 127(8):1238-1245, 2021. e-Pub 2021. PMID: 33320343.
27. Dummer, R, Lear, JT, Guminski, A, Leow, LJ, Squittieri, N, Migden, MR. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma. Journal of the American Academy of Dermatology 84(4):1162-1164, 2021. e-Pub 2021. PMID: 33358380.
28. Migden, MR, Farberg, AS, Dummer, R, Squittieri, N, Hanke, CW. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. Journal of Drugs in Dermatology 20(2):156-165, 2021. e-Pub 2021. PMID: 33538567.
29. Amit M, Liu C, Netto Gleber FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer 144:169-177, 2021. e-Pub 2021. PMID: 33352413.
30. Aboul-Fettouh N, Morse D, Patel J, Migden MR. Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma. Dermatol Pract Concept 11(Suppl 2):e2021169S, 2021. e-Pub 2021. PMID: 34877077.
31. Drummer R, Migden MR, eg. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE22 Treatment (BOLT) trial at 42 months. Journal of the American Academy of Dermatology 84(4):1162-1164, 2020. e-Pub 2020. PMID: 33385380.
32. Aria AB, Rosenbaum LE, Migden MR. Multiple inguinal basal cell carcinomas in the setting of intertrigo. Indian J Dermatol Venereol Leprol 86(4):469, 2020. e-Pub 2020. PMID: 31710000.
33. Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, Combemale P, Dirix L, Kaatz M, Kudchadkar R, Loquai C, Plummer R, Schulze HJ, Stratigos AJ, Trefzer U, Squittieri N, Migden MR. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase 2 randomised, double-blind BOLT study. Br J Dermatol 182(6):1369-1378, 2020. e-Pub 2020. PMID: 31545507.
34. Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32554615.
35. Migden MR, Chandra S, Rabinowits G, Chen CI, Desai J, Seluzhytsky A, Sasane M, Campanelli B, Chen Z, Freeman ML, Ibrahim SF, Khushalani NI, Andria M, Ruiz E. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol 16(4):11-19, 2020. e-Pub 2020. PMID: 31951149.
36. Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 21(2):294-305, 2020. e-Pub 2020. PMID: 31952975.
37. Tam S, Yao CMK, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, El-Naggar A, Migden M, Wong M, Glisson B, Ferrarotto R, Esmaeli B, Rosenthal D, Li G, Weber RS, Myers JN, Gross ND. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. e-Pub 2019. PMID: 31804658.
38. Phadnis SS, Chen L, Wang WL, Migden MR, Zaky W. Disseminated anaplastic pleomorphic xanthoastrocytoma with posttreatment fat necrosis during combined BRAF and MEK inhibitors therapy. Pediatr Blood Cancer 66(12):e27974, 2019. e-Pub 2019. PMID: 31502413.
39. Ahmed SR, Petersen E, Patel R, Migden MR. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol 12(10):947-951, 2019. e-Pub 2019. PMID: 31524530.
40. Silapunt S, Agwu AV, Migden MR. Severe pretibial myxedema refractory to systemic immunosuppressants. Cutis 104(3):E1-E3, 2019. e-Pub 2019. PMID: 31675401.
41. Petersen ET, Ahmed SR, Chen L, Silapunt S, Migden MR. Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. Future Oncol 15(27):3171-3184, 2019. e-Pub 2019. PMID: 31382778.
42. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, Investigators EB. Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 19(1):366, 2019. e-Pub 2019. PMID: 30999949.
43. Sundaresan S, Migden MR, Silapunt S. Treatment of Leg Veins for Restless Leg Syndrome: A Retrospective Review. Cureus 11(4):e4368, 2019. e-Pub 2019. PMID: 31192073.
44. Fedda F, Migden MR, Curry JL, Torres-Cabala CA, Tetzlaff MT, Aung PP, Prieto VG, Ivan D, Myers JN, Nagarajan P. Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. J Cutan Pathol 46(2):152-158, 2019. e-Pub 2019. PMID: 30414196.
45. Chen L, Aria AB, Silapunt S, Migden MR. Emerging Non-Surgical Therapies for Locally Advanced and Metastatic Non-Melanoma Skin Cancer. Dermatol Surg 45(1):1-16, 2019. e-Pub 2019. PMID: 30045105.
46. Aria A, Chen L, Rosenbaum LE, Migden MR. Mohs Micrographic Surgery for the Treatment of Cutaneous Metastases in a Patient With Papillary Thyroid Carcinoma. Dermatol Surg 44(11):1457-1459, 2018. e-Pub 2018. PMID: 29293107.
47. Yao C, Swaby MG, Migden MR, Silapunt S. A nodular Hidradenoma of atypical location in pregnancy. Acta Derm Venereol 98(9):908-909, 2018. e-Pub 2018. PMID: 29856466.
48. Chen L, Parsons AM, Aria AB, Ciurea AM, Patel AB, Chan C, Griffin JR, Nguyen TH, Migden MR. Surgical Site Identification with Personal Digital Device: A Prospective Pilot Study. J Am Acad Dermatol 79(3):520-524, 2018. e-Pub 2018. PMID: 29524583.
49. Rosenbaum LE, Migden MR. Tender Subcutaneous Fluctuant Forehead Nodule: An Unexpected Foray Into the Cranium. Dermatol Surg 44(9):1224-1227, 2018. e-Pub 2018. PMID: 29315144.
50. Migden MR. Targeted therapies in the treatment of advanced basal cell carcinoma. Clinical Research and Trials 4(4):1-6, 2018. e-Pub 2018.
51. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 379(4):341-351, 2018. e-Pub 2018. PMID: 29863979.
52. Saporito RC, Lopez-Pineiro M, Migden MR, Silapunt S. Recognizing Skin Popping Scars: A Complication of Illicit Drug Use. Cureus 10(6):e2726, 2018. e-Pub 2018. PMID: 30083487.
53. Morse DC, Tschen JA, Migden MR, Silapunt S. A Vascular-appearing Spindle Cell Xanthogranuloma in a Child. Cureus 10(5):e2595, 2018. e-Pub 2018. PMID: 30009107.
54. Migden MR. Quality of Life in Advanced Basal Cell Carcinoma and Treatment with Hedgehog Inhibitors. Journal of Clinical Trials & Research, 2018. e-Pub 2018.
55. Balasubramanyam S, Migden MR, Silapunt S. Venous Treatment of Lipodermatosclerosis to Improve Ambulatory Function. Dermatol Surg 44(5):749-752, 2018. e-Pub 2018. PMID: 28858931.
56. Chen L, Aria AB, Silapunt S, Lee HH, Migden MR. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol 14(6):515-525, 2018. e-Pub 2018. PMID: 29119833.
57. Freemyer BD, Migden MR, Silapunt S. Linear Terra Firma-Forme Dermatosis of the Midline Back. Cutis 101(3):205-206, 2018. e-Pub 2018. PMID: 29718014.
58. Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R. Long-Term Efficacy and Safety of Sonidegib in Patients With Locally Advanced and Metastatic Basal Cell Carcinoma: 30-Month Analysis of the Randomized Phase 2 BOLT Study. J Eur Acad Dermatol Venereol 32(3):372-381, 2018. e-Pub 2018. PMID: 28846163.
59. Bendell JC, Andre VA, Ho AL, Kudchakar R, Migden MR, Infante JR, Tiu RV, Pitou C, Tucker T, Brail L, VonHoff DD. Phase 1 study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment naive and previously treated basal cell carcinoma. Clin Cancer Res. e-Pub 2018. PMID: 29483143.
60. Li JY, Silapunt S, Migden MR, McGinness JL, Nguyen TH. Mohs Mapping Fidelity: Optimizing Orientation, Accuracy, and Tissue Identification in Mohs Surgery. Dermatol Surg 44(1):1-9, 2018. e-Pub 2018. PMID: 28654580.
61. English CA, Chen L, Migden MR. Traction haemostasis. Australas J Dermatol. e-Pub 2017. PMID: 29243226.
62. Migden MR. Quality of Life for Patients with Advanced Basal Cell Carcinoma Treated with Hedgehog Signaling Pathway Inhibitors. J Clinical Experimental Dermatology Research, 2017. e-Pub 2017.
63. Rosales Santillan M, ATajnert K, Swaby MG, Migden MR, Silapunt S. Multiple eccrine spiradenomas in a zosteriform pattern. Dermatol Online J 23(8), 2017. e-Pub 2017. PMID: 29469747.
64. Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB. Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. J Am Acad Dermatol 77(1):55-62.e3, 2017. e-Pub 2017. PMID: 28392293.
65. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, Investigators EB. Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma: Final Update of the Pivotal ERIVANCE BCC Study. BMC Cancer 17(1):332, 2017. e-Pub 2017. PMID: 28511673.
66. Li JY, Nguyen TN, Migden MR. Fat Plication: A Novel Technique for High Tension Wound Closure. Clinics in Surgery 2:1-2, 2017. e-Pub 2017.
67. Wu W, Chavez-Frazier A, Migden M, Nguyen T. The Buried Half Horizontal, Half Vertical Mattress Suture: A Novel Technique for Wound Edges of Unequal Lengths. Dermatol Surg 42(12):1391-1393, 2016. e-Pub 2016. PMID: 27427995.
68. Migden M. Hedgehog pathway inhibitor therapy in basal-cell nevus syndrome. Lancet Oncol 17(12):1631-1632, 2016. e-Pub 2016. PMID: 27838223.
69. Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged >/=65 years with advanced basal cell carcinoma. Oncotarget 7(46):76118-76124, 2016. e-Pub 2016. PMID: 27764798.
70. Chang AS, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day B, McKenna E, Sekulic A. Safety and Efficacy of Vismodegib in Patients aged >65 years with advanced basal cell carcinoma. Oncotarget 7(46):1949-2553, 2016. e-Pub 2016.
71. Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis 11(1):120, 2016. e-Pub 2016. PMID: 27581207.
72. Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol 8(5):375-82, 2016. e-Pub 2016. PMID: 27583029.
73. Chen L, Silapunt S, Migden MR. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of Sonidegib and the BOLT trial with 12-month update. Future Oncol 12(18):2095-105, 2016. e-Pub 2016. PMID: 27189494.
74. Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 2016. PMID: 27574101.
75. Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 75(1):113-125.e5, 2016. e-Pub 2016. PMID: 27067394.
76. Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol 160(2):220-227.e2, 2015. e-Pub 2015. PMID: 25935097.
77. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A, investigators EB. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 72(6):1021-1026.e8, 2015. e-Pub 2015. PMID: 25981002.
78. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomised, double-blind phase 2 trial. Lancet Oncol 16(6):716-28, 2015. e-Pub 2015. PMID: 25981810.
79. Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ. Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 27(3):327-41, 2015. e-Pub 2015. PMID: 25759019.
80. Lim L, Nichols B, Migden MR, Rajaram N, Reichenberg JS, Markey MK, Ross MI, Tunnell JW. Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis. J Biomed Opt 19(11):117003, 2014. e-Pub 2014. PMID: 25375350.
81. Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol 52(7):856-61, 2013. e-Pub 2013. PMID: 23675612.
82. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171-9, 2012. e-Pub 2012. PMID: 22670903.
83. Rajaram N, Reichenberg JS, Migden MR, Nguyen TH, Tunnell JW. Pilot clinical study for quantitative spectral diagnosis of non-melanoma skin cancer. Lasers Surg Med 42(10):716-27, 2010. e-Pub 2010. PMID: 21246575.
84. Rajaram N, Kovacic D, Midgen M, Reichenberg JS, Nguyen TH, Tunnell JW. In vivo determination of optical properties and fluorophore characteristics of non-melanoma skin cancer. Proceedings of the SPIE 7161:716102-716102-9, 2009. e-Pub 2009.
85. Migden M, Chavez-Frazier A, Nguyen T. The Use of High Definition Video Modules for Delivery of Informed Consent and Wound Care Education in the Mohs Surgery Unit. Semin Cutan Med Surg 27(1):89-93, 2008. e-Pub 2008. PMID: 18486030.
86. Cowl CT, Prakash U, Mitchell PS, Migden MR. Varicella-Zoster Virus Detection by Polymerase Chain Reaction Using Bronchoalveolar Lavage Specimens. Am J Respir Crit Care Med 162, 2 Pt 1:753-754, 2000. e-Pub 2000.
87. Migden MR, Dennis WH, Clinch TE. Confirmatory Testing for Hepatitis B Surface Antigen in Processing Donor Tissue for Penetrating Keratoplasty. American Journal of Ophthalmology 122:439-442, 1996. e-Pub 1996.
88. Migden MR, Elkins BS, Clinch TE. Phototherapeutic Keratectomy for Corneal Scars. Ophthalmic Surgery and Lasers 5:S503-S507, 1996. e-Pub 1996.
89. Migden MR, Kling S, Araneo BA, Perkins SL, Trautman MS. Interleukin -10 Expression in Murine Bone Marrow Macrophages. Clinical Research 41:1:19A, 1993. e-Pub 1993.

Review Articles

1. Stull CM, Clark D, Parker T, Idriss MH, Patel VA, Migden MR. Current and emerging intralesional immunotherapies in cutaneous oncology. J Am Acad Dermatol 91(5):910-921, 2024. e-Pub 2024. PMID: 38942173.
2. Idriss MH, Stull CM, Migden MR. Treatments on the horizon for locally advanced basal cell carcinoma. Cancer Lett 589:216821, 2024. e-Pub 2024. PMID: 38521198.
3. Stafford H, Buell J, Chiang E, Ramesh U, Migden M, Nagarajan P, Amit M, Yaniv D. Non-Melanoma Skin Cancer Detection in the Age of Advanced Technology: A Review. Cancers (Basel) 15(12), 2023. e-Pub 2023. PMID: 37370703.
4. Chiang E, Stafford H, Buell J, Ramesh U, Amit M, Nagarajan P, Migden M, Yaniv D. Review of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma. Cancers (Basel) 15(9), 2023. e-Pub 2023. PMID: 37173918.
5. Aboul-Fettouh N, Kubicki SL, Chen L, Silapunt S, Migden MR. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer. Dermatol Clin 41(1):23-37, 2023. e-Pub 2023. PMID: 36410980.
6. Chen OM, Kim K, Steele C, Wilmas KM, Aboul-Fettouh N, Burns C, Doan HQ, Silapunt S, Migden MR. Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35954384.
7. Burns C, Kubicki S, Nguyen QB, Aboul-Fettouh N, Wilmas KM, Chen OM, Doan HQ, Silapunt S, Migden MR. Advances in Cutaneous Squamous Cell Carcinoma Management. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35954316.
8. Aboul-Fettouh N, Chen L, Ma J, Patel J, Silapunt S, Migden M. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis. Australas J Dermatol 63(1):36-42, 2022. e-Pub 2022. PMID: 34699068.
9. Doan HQ, Chen L, Nawas Z, Lee HH, Silapunt S, Migden M. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Oncotarget 12(20):2089-2100, 2021. e-Pub 2021. PMID: 34611482.
10. Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging Trends in the Treatment of Advanced Basal Cell Carcinoma. Cancer Treat Rev 64:1-10, 2018. e-Pub 2018. PMID: 29407368.
11. Sundaresan S, Migden MR, Silapunt S. Stasis Dermatitis: Pathophysiology, Evaluation, and Management. Am J Clin Dermatol 18(3):383-390, 2017. e-Pub 2017. PMID: 28063094.
12. Doan HQ, Silapunt S, Migden MR. Sonidegib, a novel Smoothened inhibitor for the treatment of advanced basal cell carcinoma. Onco Targets Ther 14(9):5671-5678, 2016. e-Pub 2016. PMID: 27695345.

Professional Educational Materials

1. Patel K, Migden M. Mohs Micrographic Surgery: Chemotherapeutic Agents Used in Cutaneous Oncology, 2025.
2. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, Tripathi M, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma: 30-Month Final Update of the Pivotal ERIVANCE BCC Study. AAD-W (2015) American Academy of Dermatology - 73rd Annual Meeting, 2015.
3. Chang ALS, Lewis K, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna E, Sekulic A. Safety and Efficacy of Vismodegib in Elderly Patients: Analysis of the ERIVANCE BCC and Expanded Access Studies. FALLCDC (2014) Fall Clinical Dermatology Conference - 33rd Anniversary, 2014.
4. Chang ALS, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna E, Sekulic A. Safety and Efficacy of Vismodegib in Patients With Basal Cell Carcinoma Nevus Syndrome: Analysis of the ERIVANCE BCC and Expanded Access Studies. FALLCDC (2014) Fall Clinical Dermatology Conference - 33rd Anniversary, 2014.
5. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao C. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma. Final update (30-month) of the pivotal ERIVANCE BCC study. American Society of Clinical Oncology 50th Annual meeting, 2014.
6. Lewis K, Sekulic A, Hauschild A, Migden MR, Oro A, LoRusso P, Rudin C. Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies. American Society of Clinical Oncology 50th Annual Meeting, 2014.
7. Sekulic A, Hauschild A, Migden MR, et al. Survival of Patients with Metastatic Basal Cell Carcinoma and Distant Metastases: the Effect of Vismodegib, a Hedgehog Pathway Inhibitor, 2013.
8. Sekulic A, Migden M, Oro A, Lewis K, Hainsworth J, Solomon J, Yoo S, Arron S, Friedlander P, Marmur E, Radin C, Chang A, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and Safety of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 12-Month Update Of The Erivance BCC Study. Society of Melanoma Research (SMR), 2012.
9. Sekulic A, Migden MR, Oro A, Lewis K, Hainsworth JD, Yoo S, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): 12-month ERIVANCE BCC study update. ESMO (2012) European Society of Medical Oncology, 2012.
10. Sekulic A, Migden MR, Oro A, Lewis K, Hainsworth JD, Yoo S, Dirix L, Hou J, Yue E, Hauschild A. Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): Erivance BCC study update. ASCO (2012) American Society of Clinical Oncology - 48th Annual Meeting, 2012.
11. Sekulic A, Migden MR, Oro AE Dirix L, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Caro I, Mackey HM, Yauch RL, Reddy JC, Hauschild A. A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. AAD-W (2012) American Academy of Dermatology - 70th Annual Meeting, 2012.
12. Hauschild A, Migden M, Oro A, Lewis K, Hainsworth J, Yoo S, Dirix L, Hou J, Yue H, Sekulic A. 12-Month update of the erivance Basal Cell Carcinoma (BCC) study: Efficacy and Safety of the Hedgehog pathway inhibitor vismodegib in patients with metastatic and locally advanced BCC. European Association of Dermato-Oncology (EADO), 2012.
13. Chang A, Sekulic A, Migden MR, Hauschild A, Lewis K, Hainsworth J, Yoo S, Dirix L, Hou J, Mackey H, Oro A. Efficacy and Safety of Vismodegib in Advanced Basal Cell Carcinoma. Society for Investigative Dermatology (SID) 2012, 2012.

Other Articles

1. Nguyen QB, Patel J, Migden M Repair of an Extensive Defect of the Left Central Cheek. Dermatol Surg 49(1):77-79, 2023. PMID: 35125443.

Abstracts

1. Migden MR, Kheterpal M, Moody B, Patel K, Lionnet L, Sivam S, Conti J, Squittieri N, Farberg A. Efficacy Following Discontinuation of Sonidegib Treatment in Patients with Locally Advanced Basal Cell Carcinoma: Results From the BOLT 42-Month Analysis. 2023 Fall Clinical Dermatology Conference, 2024. e-Pub 2024.
2. Hughes BGM, Grob JJ, Bowyer SE, Day F, Ladwa R, Stein B, Munoz-Couselo E, eg BN. Phase 2 confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6 (enc). EADO European Association of Dermato-Oncology, Rome, Italy, 2023. e-Pub 2023.
3. Migden MR, Schmults CD, Khushalani NI, Guminski A, Chang ALS, eg LK. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1,2 and 3 (enc). EADO European Association of Dermato-Oncology, Rome, Italy, 2023. e-Pub 2023.
4. Migden MR. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2 and 3. European Society for Medical Oncology, 2022. e-Pub 2022.
5. Migden MR. An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS). American Society of Clinical Oncology, 2022. e-Pub 2022.
6. Nguyen B, Patel J, Migden MR. Repair of an Extensive Defect of the Left Central Cheek Utilizing a Cervicofacial Rotation Flap with a Retroauricular Transposed Lobe. Virtual: Texas Dermatological Society Annual Spring Meeting, 2021. e-Pub 2021.
7. Chrysalyne D, Guminski A, Chang AL, Lewis K, Lim A, Hughes B, Stankevich E, Booth J, Li S, Okoye E, Lowy I, Fury M, Migden MR. Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. American Society of Clinical Oncology Virtural meeting, 2020. e-Pub 2020.
8. Migden, MR. Efficacy of sonidegib in patients taking concomitant cardiovascular medications. American Academy of Dermatology, Denver, Co, 2020. e-Pub 2020.
9. Migden, MR. Efficacy of sonidegib in patients taking common concomitant mediations. American Academy of Dermatology, Denver, Co, 2020. e-Pub 2020.
10. Migden MR, Squittieri N. Subanalyses of Objective Response Rates: Final 42-Month Results from the BOLT Study. American Society of Dermatologic Surgery, Chicago, IL, 2019. e-Pub 2019.
11. Migden MR: Squittieri N, Lewis K. Efficacy and Safety of Sonidegib in Patients with Aggressive and Nonaggressive Subtypes of Locally Advanced Basal Cell Carcinoma: Long-Term 42 Month Results from the BOLT Studay. American Society of Dermatologic Surgery, Chicago, IL, 2019. e-Pub 2019.
12. Migden MR, Khushalani N, Chang A, Rischin D, Schmults C, Hernandez-Aya L, Meier F, Schadendord D, Guminski A, Hauschild A, Wong D, Daniels G, Berking C, Jankovic V, Stankevich E Booth J, Li S, Lowy I, Fury M, Lewis K. Ph2 primary analysis: cemiplimab, a human monoclonal anti‒PD-1, in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC). 2019 American Society of Dermatologic Surgery, Chicago, IL, 2019. e-Pub 2019.
13. Migden MR, Schlesinger T, Schmults C, Dinehart S, Ferris R, Freeman M, Guild V, Koyfman S, Pavlick A, Wolf G, Rabinowits G, Swanson N. A Multidisciplinary Consensus on the Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma. 2019 Fall Clinical Dermatology Conference, Las Vegas, NV, 2019. e-Pub 2019.
14. Migden MR, Khushalani N, Chang A, Rischin D, Schmults C, Hernandez-Aya L, Meier F, Schadendord D, Guminski A, Hauschild A, Wong D, Daniels G, Berking C, Jankovic V, Stankevich E Booth J, Li S, Lowy I, Fury M. Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC). American Society of Clinical Oncology, Chicago IL, 2019. e-Pub 2019.
15. Guminski A, Lim A, Khushalani N, Schmults C, Hernandez-Aya L, Modi B, Dunn L, Hughes B, Chang A, Hauschild A, Migden MR, Gutzmer R. Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. American Society of Clinical Oncology, Chicago IL, 2019. e-Pub 2019.
16. Morse DC, Tschen JA, Migden MR, Silapunt S. A Vascular-appearing Spindle Cell Xanthogranuloma in a Child. 24th World Congress of Dermatology, Milan, Italy, 2019. e-Pub 2019.
17. Duke T, Welborn M, Damodaran S, Prieto V, Nagarajan P, Torres-Cabala C, Curry J, Migden MR, Doan H. Atypical squamous epithelial eruptions induced by Nivolumab and NKTR-214 combination immunotherapy. 2019 Annual Texas Dermatological Society Spring Meeting, 2019. e-Pub 2019.
18. Garcia A, Petersen E, Migden MR. Reconstruction of a complex auricular defect with conchal floor flap. 2019 Annual Texas Dermatological Society Spring Meeting, 2019. e-Pub 2019.
19. Migden MR, Guminski A, Lewis K, Khushalani N, Papadopoulos K, Gao B, Patel Y, Andria M, Fury M, Rischin D. Cemiplimab, a human monoclonal antibody to PD-1, in patients with advanced cutaneous squamous cell carcinoma (CSCC): Clinical experience from the phase 1 and phase 2 studies. American Academy of Dermatology, Washington, DC, 2019. e-Pub 2019.
20. Migden MR. Treatment of Advanced Basal Cell Carcinoma with Sonidegib: Duration of Response and Quality of Life Evaluation from BOLT. European Society of Medical Oncology, Munich Germany, 2018. e-Pub 2018.
21. Chen L, Li JY, Silapunt S, Migden MR, McGinness JL, Nguyen TH. Tissue Orientation Integrity in Mohs Micrographic Surgery: A Review of Common Variations of Tissue Mapping, Orientating and Processing. 14th European Association of Dermato-Oncology (EADO) and the 9th World Meeting of interdisciplinary Skin Cancer/Melanoma Centers. Barcelona, Spain, 2018. e-Pub 2018.
22. Silapunt S, Migden MR. Lipodermatosclerosis: Understanding the skin changes. 27th European Academy of Dermatology and Venereology Congress, Paris France, 2018. e-Pub 2018.
23. Migden MR, Lewis KD. Efficacy and Safety of Sonidegib in Advanced Basal Cell Carcinoma: 42-month Final Analysis From BOLT. Dermatology Education Foundation, Las Vegas, Nevada, 2018. e-Pub 2018.
24. Migden MR, Lewis KD. The Effect of Sonidegib Dose Reductions on Efficacy in Locally Advanced Basal Cell Carcinoma: 42-month Data From BOLT. Dermatology Education Foundation, Las Vegas, Nevada, 2018. e-Pub 2018.
25. Migden MR, Dummer R. Time to Tumor Response and Planned Subgroup Analyses From the 30-month Analysis of BOLT: Treatment of Advanced Basal Cell Carcinoma With Sonidegib. Dermatology Education Foundation, Las Vegas, Nevada, 2018. e-Pub 2018.
26. Lewis K, Migden MR. Sonidegib Efficacy in Patients with Locally Advanced Basal Cell Carcinoma: An Analysis of Aggressive Versus Non-Aggressive Tumor Subtypes. Dermatology Education Foundation, Las Vegas, Nevada, 2018. e-Pub 2018.
27. Migden MR, Dummer R. Time to Tumor Response and Planned Subgroup Analyses From the 30-month Analysis of BOLT: Treatment of Advanced Basal Cell Carcinoma With Sonidegib. 2018 Maui Derm Summer NP & PA, Colorado Springs, CO, 2018. e-Pub 2018.
28. Lewis KD, Migden MR. Effects of Sonidegib Dose Reduction or Delay in Locally Advanced Basal Cell Carcinoma: 42-Month Data From BOLT. International Society of Dermatologic Surgery, Rome Italy, 2018. e-Pub 2018.
29. Migden MR, Lewis KD. 42-Month Follow-up of Sonidegib Efficacy and Safety in Advanced Basal Cell Carcinoma: Final Analysis From BOLT. International Society of Dermatologic Surgery, Rome Italy, 2018. e-Pub 2018.
30. Migden MR. Sonidegib Efficacy in Patients with Locally Advanced Basal Cell Carcinoma: An Analysis of Aggressive Versus Non-Aggressive Tumor Subtypes. 2018 Maui Derm Summer NP & PA, Colorado Springs, CO, 2018. e-Pub 2018.
31. Chen L, Aria AB, Silapunt S, Migden MR. Hedgehog Pathway Inhibitors for Locally Advanced and Metastatic Basal Cell Carcinoma as well as Basal Cell Nevus Syndrome. 15th European Academy of Dermatology and Venereology Spring Symposium, Budva, Montenegro, 2018. e-Pub 2018.
32. Lear JR, Migden MR. Sonidegib Preplanned Subgroup Analyses of Objective Response Rates: 30-Month Results from the BOLT Study. 2018 American Academy of Dermatology Annual Meeting, San Diego, CA, 2018. e-Pub 2018.
33. Migden MR, Dummer R. Time to Tumor Response and Planned Subgroup Analyses from the BOLT trial for Sonidegib in Advanced BCC. 2018 American Academy of Dermatology Annual Meeting, San Diego, CA, 2018. e-Pub 2018.
34. Chen L, Aria AB, Silapunt S, Migden MR. The Use of PD-1 Inhibitors for Locally Advanced and Metastatic Non-Melanoma Skin Cancer. American Society for Dermatologic Surgery (ASDS) Annual Meeting, Chicago, IL, 2017. e-Pub 2017.
35. Migden MR, Dummer R, Guminski A, Kudchadkar RR, eg. Sonidegib for Patients with Advanced Basal Cell Carcinoma: Long-term Efficacy and Safety Results in the BOLT 30-month analysis. 13th International Congress of the Society for Melanoma Research (SMR), Boston, Massachusetts, 2016. e-Pub 2016.
36. Sundaresan S, Migden MR, Silapunt S. Exercise Induced Vasculitis in a Patient with Negative Ultrasound Venous Reflux Study: A Mimic of Stasis Dermatitis. 25th European Academy of Dermatology and Venereology Congress, 2016. e-Pub 2016.
37. Dummer R, Migden MR, Guminski A, Gutzmer R, Kudchadkar R, Lewis K, Dirix L, eg. Investigator-Assessed Efficacy and Safety of Sonidegib in Patients with Locally Advanced Basal Cell Carcinoma and Metastatic Basal Cell Carcinoma: Results of the BOLT 30- month Analysis. 12th European Association of Dermato Oncology (EADO), 2016. e-Pub 2016.
38. Lear J, Guminski A, Gutzmer R, Migden MR, Kudchadkar R, Lewis K, Dirix L, eg. Sonidegib safety in patients with locally advanced basal cell carcinoma (laBCC) and efficacy based on tumor aggressiveness. 12th European Association of Dermato Oncology (EADO), 2016. e-Pub 2016.
39. Lear J, Guminski A, Gutzmer R, Migden MR, Kudchadkar R, Lewis K, Dirix L, eg. Sonidegib safety in patients with locally advanced basal cell carcinoma (laBCC) and efficacy based on tumor aggressiveness. 16th World Congress on Cancers of the Skin, 2016. e-Pub 2016.
40. Dummer R, Migden MR, Guminski A, Gutzmer R, Kudchadkar R, Lewis K, Dirix L, eg. Investigator-Assessed Efficacy and Safety of Sonidegib in Patients with Locally Advanced Basal Cell Carcinoma and Metastatic Basal Cell Carcinoma: Results of the BOLT 30- month Analysis. 16th World Congress on Cancers of the Skin, 2016. e-Pub 2016.
41. Migden MR, Dummer R, Guminski A, Chang A, eg. Long-Term Efficacy and Safety of Sonidegib in Patients with Locally Advanced or Metastatic Basal Cell Carcinoma: BOLT 30-Month Analysis. 2016 American Academy of Dermatology Summer meeting, 2016. e-Pub 2016.
42. Dummer R, Migden MR, Guminski A, Gutzmer R, Kudchadkar R, Lewis K, Dirix L, Combemale P, eg. Long-Term Efficacy and Safety of Sonidebig in Advanced Basal Cell Carcinoma: BOLT 30-Month Analysis. 5th Annual World Cutaneous Malignancies Congress (WCMC), 2016. e-Pub 2016.
43. Dummer R, Migden MR, Guminski A, Gutzmer R, Kudchadkar R, Lewis K, eg. Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis. American Society of Clinical Oncology, 2016. e-Pub 2016.
44. Guminski A, Stull D, Houghton K, Gutzmer R, Migden MR, Dirix L, Lewis K, Combemale P, Herd R, Kudchadkar R, Trefzer U, Sellami D, Lear J, Dummer R. Change in Fatigue and Correlations with Clinical Outcome in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib in the Bolt Study. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, 2016. e-Pub 2016.
45. Migden MR, Lear J, Guminski A, et al. Efficacy and safety of the hedgehog pathway inhibitor sonidegib in patients with locally advanced and metastatic basal cell carcinoma: BOLT 18-month analysis. American College of Mohs Surgery 2016 meeting, 2016. e-Pub 2016.
46. Chodkiewicz, Dietert J, Ranario J, Migden MR, Thomas V. The Comparison of MART-1 and MITF immunostains in Mohs Micrographic Surgery for melanoma in-situ. American College of Mohs Surgery 2016 meeting, 2016. e-Pub 2016.
47. Combemale P, Dummer R, Migden MR, Guminski A, Kewis K, Dirix L, Yi T, Sellami D, Lear J, Gutzmer R. Efficacy of sonidegib in patients with locally advanced basal cell carcinoma laBCC) by tumor burden. Melanoma and Cutaneous Malignancies Conference, New York, NY, 2016. e-Pub 2016.
48. Plummer R, Lear J, Gutzmer R, Guminski A, Yi T, Pallaud C, Zhou J, Goel V, Mone M, Sellami D, Dummer R, Migden MR. Efficacy following discontinuation of sonidegib treatment in patients with locally advanced basal cell carcinoma (laBCC). Melanoma and Cutaneous Malignancies Conference, New York, NY, 2016. e-Pub 2016.
49. Morton C, Migden MR, Yi T, Mone M, Sellami D, Dummer R. Efficacy of Sonidegib in Patients with Metastatic Basal Cell Carcinoma. Melanoma and Cutaneous Malignancies Conference, New York, NY, 2016. e-Pub 2016.
50. Migden MR, Wei J, Tang W, Herrera V, Xie J, Palmer J. Treatment Patterns and Key Factors Associated with High Treatment Costs Among Commercially-Insured Patients with Advanced Basal Cell Carcinoma. 74th Annual meeting American Academy of Dermatology, Washington, DC, 2016. e-Pub 2016.
51. Plummer R, Lear J, Gutzmer R, Guminski A, Yi T, Pallaud C, Zhou J, Goel V, Mone M, Sellami D, Dummer R, Migden MR. Efficacy of following discontinuation of sonidegib treatment in patients with locally advanced basal cell carcinoma (laBCC). Las Vegas Dermatology Seminar (LVD), 2015. e-Pub 2015.
52. Bendell J, Andre V, Ho A, Kudchadkar R, Migden MR, Infante J, Tiu R, Pitou C, Tucker T, Brail L, Hoff D. LY2940680, A Hedgehog (Hh) pathway inhibitor, demonstrates anti-tumor activity in patients with advanced basal cell carcinoma (BCC). 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2015. e-Pub 2015.
53. Dummer D, Grichnik J, Schwartz L, Gogov S, Yi T, Mone M, Sellami D, Migden MR. Composite assessment of treatment response in patients with locally advanced basal cell carcinoma (BCC): evaluation of sonidegib efficacy using two sets of response criteria. Society of Dermatology for Physician Assistants (SPDA), 2015. e-Pub 2015.
54. Plummer R, Lear J, Gutzmer R, Guminski A, Yi T, Pallaud C, Zhou J, Goel V, Mone M, Sellami D, Dummer R, Migden MR. Efficacy following Discontinuation of sonidegib treatment in patients with locally advanced basal cell carcinoma (laBCC). Society of Dermatology for Physician Assistants (SPDA), 2015. e-Pub 2015.
55. Combemale P, Dummer R, Migden MR, Guminski A, Lewis K, Dirix L, Yi T, Burnett P, Sellami D, Lear J, Gutzmer R. Efficacy of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) by tumor burder. Las Vegas Dermatology Seminar (LVD), 2015. e-Pub 2015.
56. Dummer R, Grichnik J, Schwartz L, Gogov S, Yi T, Mone M, Sellami D, Migden MR. Composite assessment of treatment response in patients with locally advanced basal cell carcinoma (BCC): evaluation of sonidegib efficacy using two sets of response criteria. Las Vegas Dermatology Seminar (LVD), 2015. e-Pub 2015.
57. Combemale P, Dummer R, Migden MR, Guminski A, Lewis K, Dirix L, YI T, Burnett P, Sellami D, Lear J, Gutzmer R. Efficacy of Sonidegib in Patients with Locally Advanced Basal Cell Carcinoma (laBCC) by tumor burden. Society of Dermatology for Physician Assistants (SPDA), 2015. e-Pub 2015.
58. Migden MR, Wei J, Tang W, Herrera V, Xie J, Palmer J. Comorbidities, Healthcare Utilization, and Cost of Advanced Basal Cell Carcinoma Among Commercially Insured Patients. Gold Metal Award: Academy of Managed Care Pharmacy, 2015. e-Pub 2015.
59. Gutzmer R, Migden MR, Sondak V, et al. Response to hedgehog pathway inhibitor therapy in patients with locally advanced basal cell carcinoma: composite assessments using 2 sets of response criteria. 24th European Academy of Dermatology and Venereology, Copenhagen, Denmark, 2015. e-Pub 2015.
60. Morton C, Migden MR, Yi T, Mone M, Sellami D, Dummer R. Efficacy of Sonidegib in Patients With Metastatic Basal Cell Carcinoma. 11th EADO Congress & 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Center, 2015. e-Pub 2015.
61. Lear J, Guminski A, Gutzmer R, et al. A phase 2, randomized, double-blind study of sonidegib (LDE225) in patients with advanced basal cell carcinoma: the BOLT 18-month analysis. 24th European Academy of Dermatology and Venereology, Copenhagen, Denmark, 2015. e-Pub 2015.
62. Lear J, Migden MR, Guminski A, et al. Efficacy of sonidegib in patients with aggressive and nonaggressive subtypes of locally advanced basal cell carcinoma. 24th European Academy of Dermatology and Venereology, Copenhagen, Denmark, 2015. e-Pub 2015.
63. Dummer R, Sondak V, Grichnik J, et al. BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria. 18th ECCO - 40th ESMO European Cancer Congress, Vienna, Austria, 2015. e-Pub 2015.
64. Drummer R, Sondak V, Grichnik J, Schwartz L, Guminski A, Gutzmer R, Yi T, Trylesinski A, Sellami D, Migden, MR. BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria. European Cancer Congress (ECCO) 2015, 2015. e-Pub 2015.
65. Dummer R, Sondak V, Grichnik J, Schwartz L, Guminski A, Gutzmer R, Yi T, Trylesinski A, Sellami D, Migden MR. BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and evaluation of tumor response using 2 sets of composite assessment criteria. 18th ECCO- 40th ESMO European Cancer Congress, Vienna, Austria, 2015. e-Pub 2015.
66. Dummer R, Gutzer R, Guminski A, Dirix L, Lewis K, Combemale P, Herd R, Gogov S, Yi T, Mone M, Kudchadkar R, Trefzer U, Lear J, Sellami D, Migden MR. A Phase 2 Randomized, Double-Blind Study of Sonidegib (LDE225) in Patients With Locally Advanced or metastatic Basal Cell Carcinoma: Updated Data From BOLT. ADO German Skin Congress 2015, Munich Germany, 2015. e-Pub 2015.
67. Trahan L, Migden MR. Body Image in Patients with Head and Neck Cancer: Predictors of Adjustment during Reconstructive Treatment. 2015 World Congress of Psycho-Oncology(794), 2015. e-Pub 2015.
68. Dummer R, Sondak V, Grichnik J, Gogov S, Yi T, Mone M, Trylesinski D, Sellami D, Migden MR. Composite assessment of treatment response in patients with locally advanced basal cell carcinoma: sonidegib efficacy using 2 sets of response criteria. World Cutaneous Malignancies Congress, 2015. e-Pub 2015.
69. Dummer R, Gutzmer R, Giminski A, et al. A Phase 2 Randomized, Double-Blind Study of Sonidegib (LDE225) in Patients with Locally Advanced or metastatic Basal Cell Carcinoma: Updated Data from BOLT. 23rd World Congress of Dermatology, Vancouver, Canada, 2015. e-Pub 2015.
70. Dummer R, Grichnik J, Schwartz L, et al. Composite assessment of treatment response in patients with locally advanced basal cell carcinoma (laBCC): efficacy with sonidegib using 2 sets of response criteria. 5th European Post-Chicago Melanoma/Skin Cancer Meeting, Munich, Germany, 2015. e-Pub 2015.
71. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Genomic Drivers of Cutaneous Squamous Cell Carcinoma Development. 2015 Society for Investigative Dermatology (SID) Annual Meeting, Atlanta, GA, 2015. e-Pub 2015.
72. Dummer R, Sondak V, Grichnik J, Schwartz L, Gogov S, Yi T, Mone M, Trylesinski A, Sellami D, Migden MR. Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): Sonidegib efficacy using 2 sets of response criteria. J Clin Oncol: American Society of Clinical Oncology 33(suppl), 2015. e-Pub 2015.
73. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Genomic Drivers of Cutaneous Squamous Cell Carcinoma Development. American Society for Clinical Investigation (ASCI) and American Physician Scientists Association (APSA) Joint 11th Annual meeting, Chicago, IL, 2015. e-Pub 2015.
74. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Genomic Drivers of Cutaneous Squamous Cell Carcinoma Development. Translational Science 2015 National Conference, Washington, DC, 2015. e-Pub 2015.
75. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, Tripathi M, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma: 30-Month Final Update of the Pivotal ERIVANCE BCC Study. AAD-W (2015) American Academy of Dermatology - 73rd Annual Meeting, 2015. e-Pub 2015.
76. Migden MR, Gutzmer R, Guminski A, Yi T, Gogov S, Lear J, Dummer R. A 12-month update of BOLT, a phase 2, randomized, double-blind study of sonidegib (LDE225) in patients with locally advanced or metastatic basal cell carcinoma. J. Am Acad Dermatol: 73rd Annual Meeting of the American Academy of Dermatology 72(suppl 1), 2015. e-Pub 2015.
77. Migden MR, Lear J, Gutzmer R, Marker M, Pallaud C, Guminski A, Dummer R. Inhibition of the hedgehog pathway with sonidegib (LDE225) in advanced basal cell carcinoma. J Am Acad Dermatol: 73rd Annual Meeting of the American Academy of Dermatology 72(suppl 1), 2015. e-Pub 2015.
78. Migden MR, Lear J, Guminski A, Yi T, Higuchi K, Gutzmer R, Dummer R. Quality of life in patients with advanced basal cell carcinoma treated with sonidegib (LDE225). J Am Acad Dermatol: 73rd Annual Meeting of the American Academy of Dermatology 72(suppl 1), 2015. e-Pub 2015.
79. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, Tripathi M, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma: 30-Month Final Update of the Pivotal ERIVANCE BCC Study. AAD-W (2015) American Academy of Dermatology - 73rd Annual Meeting, 2015. e-Pub 2015.
80. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, Tripathi M, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): final update (30-month) of the pivotal ERIVANCE BCC study. SMR (2014) Society for Melanoma Research - 11th International Melanoma Congress, 2014. e-Pub 2014.
81. Gutzmer R, Dummer R, Guminski A, et al. Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal cell carcinoma (BCC). 4th European Post-Chicago Melanoma/Skin Cancer Meeting, 2014. e-Pub 2014.
82. Gutzmer R, Migden M, Guminski A, et al. Hedgehog pathway inhibition with sonidegib (LDE225) in patients with advanced basal cell carcinoma. 23rd European Academy of Dermatology and Venereology, 2014. e-Pub 2014.
83. Migden MR, Guminski A, Gutzmer R, et al. A phase 2, randomized, double-blind study of sonidegib (LDE225) in patients (pts) with advanced basal cell carcinoma (BCC): BOLT 12-month update. 3rd World Cutaneous Malignancies Congress, San Francisco, CA, 2014. e-Pub 2014.
84. Dummer R, Gutzmer R, Migden MR, et al. Hedgehog pathway inhibition with sonidegib (LDE225) in patients with advanced basal cell carcinoma. 3rd World Cutaneous Malignancies Congress, San Francisco, CA, 2014. e-Pub 2014.
85. Guminski A, Migden MR, Gutzmer R, et al. Quality of life with sonidegib (LDE225) treatment in patients with advanced basal cell carcinoma. 3rd World Cutaneous Malignancies Congress, San Francisco, CA, 2014. e-Pub 2014.
86. Migden MR, Guminski A, Gutzmer R, et al. Phase 2 randomised study of sonidegib (LDE225) in patients with advanced basal cell carcinoma. 23rd European Academy of Dermatology and Venereology, 2014. e-Pub 2014.
87. Dummer R, Gutzmer R, Migden MR, Dirix L, Lewis K, et al. Patient-reported quality of life (QoL) with sonidegib (LDE225) in advanced basal cell carcinoma (BCC). ESMO Congress, 2014. e-Pub 2014.
88. Gutzmer R, Migden MR. BOLT-eine randomisierte, doppelblinde studie mit sonidegib (LDE225) bei patienten mit lokal fortgeschrittenem oder metastasiertem basalzellkarzinom. 24th German Skin Cancer Congress; Frankfurt, Germany, 2014. e-Pub 2014.
89. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. Society for Investigative Dermatology (SID) Annual Meeting, Albuquerque, NM, 2014. e-Pub 2014.
90. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. Translational Science 2014 National Conference; Washington, DC, 2014. e-Pub 2014.
91. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. American Society for Clinical Investigation (ASCI) and American Physician Scientists Association (APSA) Joint 10th Annual Meeting, Chicago, IL, 2014. e-Pub 2014.
92. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. Graduate School of Biomedical Sciences at Houston (GSBS) Genes and Development Retreat, Houston TX, 2014. e-Pub 2014.
93. Migden MR, Guminski AD, Gutzmer R, et al. Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC). J Clin Oncol 32(5), 2014. e-Pub 2014.
94. Sekulic A, Migden MR, Basset Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell DF, Hamid O, Quevido JF, Hou J, Tripathi M, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30-month) of the pivotal ERIVANCE BCC study. ASCO (2014) American Society of Clinical Oncology - 50th Annual Meeting, 2014. e-Pub 2014.
95. Chang ALS, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna E, Sekulic A. Safety and Efficacy of Vismodegib in Patients With Basal Cell Carcinoma Nevus Syndrome: Analysis of the ERIVANCE BCC and Expanded Access Studies. FALLCDC (2014) Fall Clinical Dermatology Conference - 33rd Anniversary, 2014. e-Pub 2014.
96. Chang ALS, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna E, Sekulic A. Safety and Efficacy of Vismodegib in Patients With Basal Cell Carcinoma Nevus Syndrome: Analysis of the ERIVANCE BCC and Expanded Access Studies. WCMC (2014) World Cutaneous Malignancies Congress - 3rd Annual, 2014. e-Pub 2014.
97. Chang ALS, Lewis K, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna E, Sekulic A. Safety and Efficacy of Vismodegib in Elderly Patients: Analysis of the ERIVANCE BCC and Expanded Access Studies. FALLCDC (2014) Fall Clinical Dermatology Conference - 33rd Anniversary, 2014. e-Pub 2014.
98. Chang ALS, Lewis K, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna E, Sekulic A. Safety and Efficacy of Vismodegib in Elderly Patients: Analysis of the ERIVANCE BCC and Expanded Access Studies. WCMC (2014) World Cutaneous Malignancies Congress - 3rd Annual, 2014. e-Pub 2014.
99. Mortier BN, L, Sekulic A, Migden MR, Garbe C, et al. Efficacy and tolerance of long term vismodegib in the basal cell carcinoma advance: final analysis of the study 30 months pivotal ERIVANCE. 2014 Annals of Dermatology and Venereology, 2014. e-Pub 2014.
100. Sekulic A, Migden MR, Oro AE Dirix L, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Caro I, Mackey HM, Yauch RL, Reddy JC, Hauschild A. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. AAD-W (2014) American Academy of Dermatology - 72nd Annual Meeting, 2014. e-Pub 2014.
101. Guminski A, Gutzmer R, Migden M, et al. Quality of life (QOL) in patients (pts) with advanced basal cell carcinoma (BCC) treated with sonidegib (LDE225). Pigment Cell Melanoma Res 27(6), 2014. e-Pub 2014.
102. Gutzmer R, Dummer R, Guminski A, et al. Sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal cell carcinoma (BCC). Pigment Cell Melanoma Res 27(6), 2014. e-Pub 2014.
103. Dummer R, Migden M, Guminski A, et al. Inhibition of the hedgehog (Hh) pathway with sonidegib (LDE225) in advanced basal cell carcinoma (aBCC). Pigment Cell Melanoma Res 27(6), 2014. e-Pub 2014.
104. Lewis K, Sekulic A, Hauschild A, Migden MR, Oro AE, LaRusso P, Rudin CM, Dirix L, Solomon JA, Hainsworth JD, Williams S, Hou J, Von Hoff DD. Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies. ASCO (2014) American Society of Clinical Oncology - 50th Annual Meeting, 2014. e-Pub 2014.
105. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, Tripathi M, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30-month) of the pivotal ERIVANCE BCC study. EADV (2014) European Academy of Dermatology and Venereology - 23rd Congress, 2014. e-Pub 2014.
106. Schadendorf D, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Hou J, Lyons B, Sekulic A. Vismodegib in advanced basal cell carcinoma: 24-month ERIVANCE update. EADO (2014) European Association of Dermato-Oncology - 10th Congress, 2014. e-Pub 2014.
107. Torres A, Tang J, Arron S, Migden M, Cockerell C, Lee S, McKenna E, Chen D. Treatment of Basal Cell Carcinoma With Oral Vismodegib Preceding Mohs Micrographic Surgery Excision: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study (NCT01898598). FALLCDC (2014) Fall Clinical Dermatology Conference - 33rd Anniversary, 2014. e-Pub 2014.
108. Dummer R, Guminski A, Gutzmer R, et al. Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with advanced basal cell carcinoma (BCC). Ann Oncol 25(suppl 4), 2014. e-Pub 2014.
109. Dummer R, Gutzmer R, Migden MR, et al. Patient-reported quality of life (QOL) with sonidegib (LDE225) in advanced basal cell carcinoma (BCC). Ann Oncol 25(suppl 4), 2014. e-Pub 2014.
110. Migden MR, Guminski A, Gutzmer R, et al. Phase 2 randomized, double-blind study of sonidegib (LDE225) in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma. Br J Dermatol: World Congress on Cancers of the Skin (WCCS) 171(supple 4):66-67, 2014. e-Pub 2014.
111. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. Texas Regional CTSA Consortium (TRCC) San Antonio, TX, 2013. e-Pub 2013.
112. Richards K, Migden MR. Treatment of Locally-Advanced Basal Cell Carcinoma with VISMODEGIB. John M. Knox, M.D. Memorial Lecture, 2013. e-Pub 2013.
113. Sekulic A, Migden MR, Ore A, Dirix L, Lewis K, Hainsworth J, Solomon J, Hou J, Lyons B, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients with Advanced Basal Cell Carcinoma (aBCC): 24-Month Update of the Pivotal ERIVANCE BCC Study. 10th International Meeting of the Society for Melanoma Research, 2013. e-Pub 2013.
114. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. Annual Medical School Research Retreat; Wilkerson Discovery Hall of the Institute of Molecular Medicine, Houston, TX, 2013. e-Pub 2013.
115. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. American Physician Scientists Association (APSA) San Antonio, TX, 2013. e-Pub 2013.
116. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. Fourth Annual Advances in Oncology, Houston, TX, 2013. e-Pub 2013.
117. Sekulic A, Migden MR, Oro A, Dirix L, Lewis K, Hainsworth J, Solomon J, Hou J, Lyons B, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. American Academy of Dermatology (AAD) 2013, 2013. e-Pub 2013.
118. Sekulic A, Hauschild A, Migden MR, Oro A, LoRusso P, Rudin C, Lewis K, Dirix L, Solomon J, Hainsworth J, Yue H, Hou J, Hoff D. Survival of Patients With Metastatic Basal Cell Carcinoma and Distant Metastases: the Effect of Vismodegib, a Hedgehog Pathway Inhibitor. 8th World Congress of Melanoma; Hamburg, Germany, 2013. e-Pub 2013.
119. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell D, Hamid O, Quevendo J, Hou J, Mackey H, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients with Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study. American Society of Clinical Oncology (ASCO) 2013, 2013. e-Pub 2013.
120. Sekulic A, Migden MR, Basset Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell DF, Hamid O, Quevido JF, Hou J, Tripathi M, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30-month) of the pivotal ERIVANCE BCC study. ASCO (2014) American Society of Clinical Oncology - 50th Annual Meeting, 2013. e-Pub 2013.
121. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Coarfa C, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. American Society for Clinic Investigation (ASCI) and American Physician Scientists Association (APSA) Joint 9th Annual Meeting; Chicago, IL, 2013. e-Pub 2013.
122. Sekulic A, Migden MR, Oro A, Dirix L, Lewis K, Hainsworth J, Solomon J, Hou J, Lyons B, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. European Academy of Dermatology and Venereology (EADV) 2013, 2013. e-Pub 2013.
123. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, et al. Efficacy and tolerance of long term vismodegib in patients presenting a basal cell carcinoma advance (CBCA):update 18 months of the study pivot ERIVANCE CBC. 2013 Annals of Dermatology and Venereology, 2013. e-Pub 2013.
124. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. Center for Cancer Immunology Research (CCIR) Retreat, Austin, TX, 2012. e-Pub 2012.
125. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Gunaratne P, Su X, Flores ER, Tsai K. Identification and Functional Analysis of Key Genetic Drivers of Cutaneous Squamous Cell Carcinoma. American Physician Scientists Association (APSA) Dallas, TX, 2012. e-Pub 2012.
126. Sekulic A, Migden MR, Oro AE, Direx L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine 366(23):2171-9, 2012. e-Pub 2012.
127. Chitsazzadeh V, Nguyen T, Thomas V, Migden MR, Joseph A, Vin H, Leung M, Gunaratne P, Su X, Tsai K. Integrated Genomic Analysis of Cutaneous Squamous Cell Carcinoma Progression. Graduate School of Biomedical Sciences at Houston (GSBS) Genes and Development Retreat Houston, TX, 2012. e-Pub 2012.
128. Murrell DF, Migden MR, Oro AE, Hauschild A, Lewis K, Solomon JA, Yoo S, Mackey H, Caro I, Sekulic A. A pivotal trial of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Australasian College of Dermatologist 45th Annual Meeting, 2012 Australia, 2012. e-Pub 2012.
129. Hauschild A, Migden MR, Oro AE, Lewis K, Hainsworth JD, Yoo S, Dirix L, Hou J, Yue H, Sekulic A. 12-month update of the erivance basal cell carcinoma (BCC) study: efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced bcc (aBCC). EADO (2012) European Association of Dermato-Oncology - 8th Congress, 2012. e-Pub 2012.
130. Sekulic A, Migden MR, Oro A, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and safety of vismodegib in patients with advanced basal cell carcinoma (BCC): 12-month update of the Erivance BCC study. SMR 2012 (2012) Society for Melanoma Research 2012 Congress, 2012. e-Pub 2012.
131. Chang ALS, Sekulic A, Migden MR, Hauschild A, Lewis K, Hainsworth JD, Yoo S, Dirix L, Hou J, Mackey H Oro AE. Efficacy and safety of vismodegib in advanced basal cell carcinoma. SID (2012) Society for Investigative Dermatology - 72nd Annual Meeting, 2012. e-Pub 2012.
132. Sekulic A, Migden MR, Oro AE, Lewis K, Hainsworth JD, Yoo S, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update. ASCO (2012) American Society of Clinical Oncology - 48th Annual Meeting, 2012. e-Pub 2012.
133. Sekulic A, Migden MR, Oro A, Dirix L, Lewis K, Hainsworth J, Solomon J, Yoo S, Arron S, Friedlander P, Marmur E, Rudin C, Chang A, Caro I, Mackey H, Yauch R, Reddy J, Hauschild A. A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. American Academy of Dermatology 2012, 2012. e-Pub 2012.
134. Sekulic A, Migden MR, Oro A, Lewis K, Hainsworth JD, Yoo S, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Basal Cell Carcinoma (BCC): 12 month ERIVANCE BCC Study Update. ESMO 2012, 2012. e-Pub 2012.
135. Migden MR, Oro AE, Hauschild A, Lewis K, Mueller AB, Yauch RL, Reddy JC, Sekulic A. Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Basal Cell Carcinoma: A Pivotal Multicenter Trial. American Society of Dermatologic Surgery 2011 Annual Meeting Washington DC, 2011. e-Pub 2011.
136. Sekulic A, Migden M, Oro A, Dirix L, Lewis K, Hainsworth J, Yoo S, Arron S, Friedlander P, Marmur E, Rudin C, Chang A, Low J, Mueller AB, Yauch R, Reddy J, Hauschild A. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. 20th European Academy of Dermatology and Venereology, 2011. e-Pub 2011.
137. Sekulic A, Migden M, Oro A, Hauschild A, Lewis K, Hainsworth J, Yoo S, Arron S, Friedlander P, Marmur E, Rudin C, Chang A, Low J, Mackey H, Yauch R, Reddy J, Dirix L. A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) GDC-0449 in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC). American Society of Clinical Oncology, 2011. e-Pub 2011.
138. Sekulic A, Migden M, Oro A, Dirix L, Lewis K, Hainsworth J, Yoo S, Arron S, Friedlander P, Marmur E, Rudin C, Change A, Low J, Mueller AB, Yauch R, Reddy J, Hauschild A. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC). 7th European Association of Dermato-Oncology, Nantes, France, 2011. e-Pub 2011.
139. Basset-Seguin N, Migden M, Oro A, Dirix I, Lewis K, Low J, Mackey H, Yauch R, Reddy J, Sekulic A. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC). JDP (2011) Journees Dermatologiques de Paris 2011, 2011. e-Pub 2011.
140. Dirix L, Migden MR, Oro AE, Hauschild A, Lewis K, Mueller AB, Yauch RL, Reddy JC, Sekulic A. A Pivotal Multicenter Trial Evaluating Efficacy and Safety of the Hedgehog Pathway Inhibitor (HPI) Vismodegib in Patients with Advanced Basal Cell Carcinoma (BCC). ECCO/European Society for Medical Oncology 36th Congress, Stockholm, 2011. e-Pub 2011.
141. Migden MR, Charles D, Siegel E. Sustaining the Reduction in Late Mohs and Dermasurgical Cases. CS&E Conference. Austin, TX, 2010. e-Pub 2010.
142. Rajaram N, Reichenberg J, Migden M, Nguyen T, Tunnell J. Pilot Clinical Study for Quantitative Spectral Diagnosis of Non-Melanoma Skin Cancer. Biomedical Optics (BIOMED), 2010. e-Pub 2010.
143. Chen TM, Wanitphakdeedecha R, Nguyen TH, Migden M. If it wasn't documented, it wasn't done. Clinical Safety and Effectiveness MD Anderson Cancer Center, 2007. e-Pub 2007.
144. Chen TM, Wanitphakdeedecha R, Migden MR, Nguyen TH. SMAS plication in facial reconstructive surgery. American College of Mohs Surgery (ACMS) Naples, FL, 2007. e-Pub 2007.
145. Chen TM, Wanitphakdeedecha R, Migden MR, Nguyen TH. Intraoperative relaxing incisions in Mohs micrographic surgery. American College of Mohs Surgery (ACMS). Naples, FL, 2007. e-Pub 2007.
146. Chen TM, Migden MR, Nguyen TH. CO2 laser ablation and adjunctive destruction for Darier's disease. American Society of Laser Medicine and Surgery. Grapevine TX, 2007. e-Pub 2007.
147. Chen TM, Wanitphakdeedecha R, Migden MR, Nguyen TH. Multi-staged reconstruction and complications in a complex surgical defect. Aesthetic Facial Reconstruction. Tucson AZ, 2007. e-Pub 2007.
148. Migden MR, Jackson ST. Post-Operative Tear Flow Following Ptosis Surgery: A Comparison of the Fasanella-Servat with the Anterior Levator Resection. Clinical Faculty Day, Moran Eye Center, 1995. e-Pub 1995.

Book Chapters

1. Sekulic, A, Migden, MR, Oro, AE, Dirix, L, Lewis, K, Hainsworth, JD, Solomon, JA, Yoo, SS, Arron, ST, Friedlander, P, Marmur, E, Rudin, CM, Chang, AS, Low, JA, Mackey, HM, Yauch, RL, Graham, RA, Reddy, JC, Hauschild, A, Maubec, E, Petrow, P, Scheer-Senyarich, I, Duvillard, P, Lacroix, L, Gelly, J, Certain, A, Duval, X, Crickx, B, Buffard, V, Basset-Seguin, N, Saez, P, Duval-Modeste, A, Bénédicte, A, Henri, M, Sandrine, G, Florent, D, Anne, F, Sandrine, M, France, A, Françoise, M, Long, GV, Hauschild, A, Santinami, M, Atkinson, VG, Mandal, M, Chiarion-Sileni, V, Larkin, J, Nyakas, M, Dutriaux, C, Haydon, A, Robert, C, Mortier, L, Schachter, J, Schadendorf, D, Lesimple, T, Plummer, R, Ji, R, Zhang, P, Mookerjee, B, Legos, JJ, Kefford, R, Dummer, R, Kirkwood, JM. Targeted therapy for cutaneous malignancies, 389-400, 2022.
2. Chen, L, Migden, MR. Systemic therapy for locally advanced and metastatic non-melanoma skin cancer, 353-366, 2021.
3. Migden MR, Chen L. Systemic Therapy for Locally Advanced and Metastatic Non-Melanoma Skin Cancer. In: Skin Cancer Management. Springer, 2021.
4. Silapunt S, Mr M. Incision and Drainage. In: Dermatologic Surgery. McGraw-Hill, 202-208, 2018.
5. Nguyen T, Migden M. Reconstruction of the Ears. In: In "Dermatologic Surgery-Step by Step". John Wiley & Sons, Ltd, 2012.
6. Migden M, Silapunt S. Mohs Micrographic Surgery of the Periorbital Area. In: Smith's Ophthalmic Plastic & Reconstructive Surgery, 3rd edition. Springer Science+Business Media, 2011.
7. Migden M. Mohs Surgery-Margin Control, Indications, and Techniques. In: Cutaneous Malignancy of the Head and Neck. Plural Publishing, Inc, 2011.

Books (edited and written)

1. Migden MR, Chen L, Silapunt S. Basal Cell Carcinoma: Advances in Treatment and Research. Ed(s) 1st. Springer, 2020.
2. Murad M, Silapunt S. Treatment of Leg Veins 2nd Edition. Elsevier, 2010.
3. Rohrer TE, Cook JL, Nguyen TH, and Mellette RJ. Flaps and Grafts in Dermatologic Surgery DVD's. Elsevier, 2007.
4. Alam M, Nguyen TH. Treatment of Leg Veins DVD. Elsevier, 2006.

Letters to the Editor

1. Bai JQA, King A, Macdonald J, Migden MR, Tan MG. Immune Checkpoint Inhibitor-Associated Squamous Cell Carcinoma: A Systematic Review. J Cutan Med Surg: 12034754251403189, 2025.
2. Aboul-Fettouh N, Chen L, Silapunt S, Migden MR. Use of PD-1 Inhibitors in the Treatment of Advanced Basal Cell Carcinoma. Dermatol Surg 47: 1511-1512, 2021.
3. Aboul-Fettouh N, Patel J, Migden MR. Do Not Mess With Tattoos? Mohs Micrographic Surgery for Basal Cell Carcinoma Within the State of Texas. Dermatol Surg 47: 1273-1275, 2021.
4. Sundaresan S, Migden MR, Silapunt S. Exercise Induced Vasculitis in a Patient with Negative Ultrasound Venous Reflux Study: A Mimic of Stasis Dermatitis. Cutis 107: E10-E11, 2021.
5. English C, Chen L, Migden MR. Traction Hemostasis. Australasian Journal of Dermatology: 156-157, 2018.
6. Migden MR. Hedgehog pathway inhibitor therapy in basal cell nevus syndrome. The Lancet Oncology 16, 2016.